Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
It is premature to make a recommendation for treatment of peripartum cardiomyopathy (PPCM) with prolactin inhibition (bromocriptine or cabergoline) as in the one-case report of Melo et al.
There are now multiple reports of trials for PPCM subjects in the use prolactin inhibition treatment compared with non-use of this modality that show no statistically significant benefit in recovery outcomes at 6 and 12 months postpartum.,
[…]
Search
Search in:
It is premature to make a recommendation for treatment of peripartum cardiomyopathy (PPCM) with prolactin inhibition (bromocriptine or cabergoline) as in the one-case report of Melo et al.
There are now multiple reports of trials for PPCM subjects in the use prolactin inhibition treatment compared with non-use of this modality that show no statistically significant benefit in recovery outcomes at 6 and 12 months postpartum.,
[...]
Comments